

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/698,160	
			Filing Date	October 30, 2003	
			First Named Inventor	YU, DE-CHAO	
			Art Unit	1945/636	
Sheet	1	of	3	Examiner Name	Guzo
				Attorney Docket Number	CELL-023

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
DG		20010006633		July 5, 2001	KIRN	
DG		20010053768		December 20, 2001	GREGORY et al.	
DG		20030026789		February 6, 2003	GREGORY et al.	
DG		20030068307		April 10, 2003	YU et al.	
DG		20030104625		June 5, 2003	CHENG et al.	
DG		20040009588		January 15, 2004	CHANG et al.	
DG		5,998,205		December 7, 1999	HALLENBECK et	
DG		6,432,700		August 13, 2002	HENDERSON et	
DG		6,551,587		April 22, 2003	HALLENBECK et	
DG		6,638,762		October 28, 2003	CHANG et al.	
DG		6,692,736		February 17, 2004	YU et al.	


FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
DG		WO	01/36650	25 May 2001	ONYX		
DG		WO	01/72341	4 Oct. 2001	CALYDON		
DG		WO	01/73093	4 Oct. 2001	CALYDON		
DG		WO	02/067861	6 Sept. 2002	NOVARTIS		
DG		WO	92/03563	5 Mar. 1992	CENTRAAL		
DG		WO	96/17053	6 June 1996	GENETIC		
DG		WO	96/34969	7 Nov. 1996	CANJI		
DG		WO	98/29555	9 July 1998	ONYX		
DG		WO	98/39464	11 Sept. 1998	CALYDON		
DG		WO	99/25860	27 May 1999	NOVARITIS		
DG		WO	99/59604	25 Nov. 1999	ONYX		
DG		WO	99/28469	10 June 1999	GENZYME		

Examiner Signature	/David Guzo/	Date Considered	06/18/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,160
				Filing Date	October 30, 2003
				First Named Inventor	YU, DE-CHAO
				Art Unit	1636
Sheet	2	of	3	Examiner Name	GUZO
				Attorney Docket Number	CELL-023
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
DG		CHEN et al., LINKAGE BETWEEN STAT REGULATION AND EPSTEIN-BARR VIRUS GENE EXPRESSION IN TUMORS, J. Virol., 2001, 75(6): 2929-2937			
DG		CHIA et al., A NOVEL CONDITIONALLY ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA (NPC), Proc. Amer. Ass. For Cancer Res., 2002, 43: 1098-1099			
DG		CHIOCCA et al., ONCOLYTIC VIRUSES, Nature Publishing Group, 2002, 2: 938-951			
DG		FENG et al., USE OF ADENOVIRUS VECTORS EXPRESSING EPSTEIN-BARR VIRUS (EBV) IMMEDIATE-EARLY PROTEIN BZLF1 OR BRLF1 TO TREAT EBV-POSITIVE TUMORS, J Virol., 2002, 76(21):10951-10959			
DG		GRINSTEIN et al., DEMONSTRATION OF EPSTEIN-BARR VIRUS IN CARCINOMAS OF VARIOUS SITES, Cancer Res., 2002, 1:62(17):4876-4878			
DG		LI et al., TUMOR-TARGETED GENE THERAPY FOR NASOPHARYNGEAL CARCINOMA, Cancer Res., 2002, 62: 171-178			
DG		REISMAN et al., TRANS ACTIVATION OF AN EPSTEIN-BARR VIRAL TRANSCRIPTIONAL ENHANCER BY THE EPSTEIN-BARR VIRAL NUCLEAR ANTIGEN 1, Molecular and Cell. Biol., 1986, 6(11): 3838-3846			
DG		SADLER et al., THE EPSTEIN-BARR VIRUS 3.5-KILOBASE LATENT MEMBRANE PROTEIN 1 MRNA INITIATES FROM A TATA-LESS PROMOTER WITHIN THE FIRST TERMINAL REPEAT, J. of Virol., 1995, 69(7): 4577-4581			
DG		SJÖBLOM et al., AN ATF/CRE ELEMENT MEDIATES BOTH EBNA2-DEPENDENT AND EBNA2-INDEPENDENT ACTIVATION OF THE EPSTEIN-BARR VIRUS LMP1 GENE PROMOTER, J. of Virol., 1998, 72(2): 1365-1376			
Examiner Signature		/David Guzo/		Date Considered	06/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known				
		Application Number	10/698,160			
		Filing Date	October 30, 2003			
		First Named Inventor	YU, DE-CHAO			
		Art Unit	1845 1636			
Sheet	3	of	3	Examiner Name	GUZO	
Attorney Docket Number						CELL-023
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
DG		TSAI et al., ADDITIVE EFFECT OF SP1 AND SP3 IN REGULATION OF THE ED-L1E PROMOTER OF THE EBV LMP 1 GENE IN HUMAN EPITHELIAL CELLS, Virology, 1999, 261: 288-294				
DG		YU et al., SELECTIVELY REPLICATING ONCOLYTIC ADENOVIRUSES AS CANCER THERAPEUTICS, Curr. Opinion in Mol. Ther., 2002, 4(5): 435-443				
DG		WAEHLER et al., EXPERIMENTAL GENE THERAPY OF HEPATOCELLULAR CARCINOMA: EXPRESSION OF IL-12, 4-1BBL AND IL-2 FROM A SINGLE ADENOVIRAL VECTOR, 10 TH Annual ESGT meeting, Oct. 13-16, 2002				
Examiner Signature		/David Guzo/			Date Considered	06/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.